CCRM is a Canadian public-private partnership established with seed funding by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development of regenerative medicine-based technologies, and cell and gene therapies. CCRM has a 40,000-square-foot space dedicated to advanced cell manufacturing that includes a GMP facility for producing cells and viral vectors. CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients with specialized teams, dedicated funding and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-scale CDMO. CCRM is hosted by the University of Toronto. Visit www.ccrm.ca.